U.S. Markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.1281%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.2601%)
     
  • USD/JPY

    113.4800
    -0.5080 (-0.4457%)
     
  • BTC-USD

    60,987.61
    +503.12 (+0.83%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

TCR2 Therapeutics Stock Plunges On Safety Signals From Gavo-cel Solid Tumor Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TCR2 Therapeutics Inc (NASDAQ: TCRR) stock dropped to a 52-week low after interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors.

  • The data will be at the European Society for Medical Oncology (ESMO21) Congress 2021.

  • Gavo-cel was administered up to dose level 5 (DL5) (5x108/m2 following lymphodepletion).

  • Two dose-limiting toxicities were reported.

  • One Grade 3 pneumonitis at DL1, which was resolved with supportive measures, and dose escalation continued.

  • One Grade 5 bronchoalveolar hemorrhage at DL5, along with severe CRS in all three patients treated at this dose level was reported.

  • The safety review team declared 5x108/m2 as the maximum tolerated dose.

  • Six patients were evaluable for response. Tumor regression was observed in 15 (94%) patients with a disease control rate (DCR) of 81%.

  • Six patients achieved partial responses (PRs) by target lesion assessment, four of whom achieved a PR.

  • The objective response rate (ORR) was 31% by independent review assessment and 38% by investigator assessment.

  • Price Action: TCRR stock dropped 31.7% at $10.74 during the market session on the last check Friday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.